-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Initiates Coverage On Kiniksa Pharmaceuticals with Buy Rating, Announces Price Target of $40

Benzinga·03/13/2025 13:40:20
Listen to the news
Citigroup analyst Geoff Meacham initiates coverage on Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Buy rating and announces Price Target of $40.